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1. Abstract 
 
Duchenne muscular dystrophy is caused by the absence of the muscle cytoskeletal protein 
dystrophin. Utrophin is a 395 kDa cytoskeletal protein with a high degree identity with 
dystrophin at the amino acid levels and is an autosomal homologue of dystrophin, and 
overexpression of utrophin is expected to compensate for the dystrophin deficit. Recently, 
Takahashi et al. (2005) reported that the 5.4 kb 5’-flanking region of the utrophin gene 
containing the A-utrophin core promoter drives high levels of transgene expression in liver, 
testis, small intestine, submandibular gland, and colon, but not in heart and skeletal muscle. To 
clarify the regulatory mechanism of utrophin expression in the present study, we generated a 
nuclear localization signal-tagged LacZ transgenic (Tg) mouse, in which the LacZ gene was 
driven by the 129 bp downstream utrophin enhancer (DUE) and the 5.4 kb 5’-flanking region of 
the utrophin promoter. The levels of transgene mRNA expression in several tissues were 
examined by reverse transcription-polymerase chain reaction (RT-PCR) and quantitative RT-
PCR (q-RT-PCR), and cryosections of several tissues were stained with hematoxylin and eosin 
(H&E) and 5-bromo-4-chloro-3-indolyl-E-D-galactopyranoside (X-gal). The expression patterns 
of the transgene were consistent with endogenous utrophin in several tissues including heart and 
skeletal muscle. Transgene expression was also up-regulated more in regenerating muscle than 
in non-regenerating muscle. Moreover, utrophin expression was augmented in the skeletal 
muscle of DUE Tg/X chromosome-linked muscular dystrophy (mdx) mice through cross-
breeding experiments. We finally established cultures of primary myogenic cells from this Tg 
mouse and found that utrophin up-regulation during muscle differentiation depends on the DUE 
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motif. These cells provide a high through-put screening system for drugs that up-regulate 
utrophin expression in muscle cells. In conclusion, DUE is indispensable for utrophin 
expression in skeletal muscle and heart.   
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2. Introduction 
 
It is generally accepted that skeletal muscles size depends upon a dynamic balance 
between catabolic (or atrophic) and anabolic (or hypertrophic) processes1). Mass and fiber size 
in adult skeletal muscle is known to be regulated to changes in workload, activity or 
pathological conditions2, 3).  Muscle hypertrophy is associated with increased protein synthesis, 
while atrophy-induced by decreases in activity and load or by catabolic agents- enhances protein 
degradation pathway1).  However, it is unclear whether hypertrophy and atrophy pathways 
operate independently or whether they can regulate one another1-3).  
Muscle atrophy occurs systematically in fasting and a variety of diseases ie., cancer, 
diabetes mellitus, AIDS, sepsis, cachexia, Cushing’s syndrome and glucocorticoid treatment and 
in specific muscles upon denervation, immobilization, suspension or disuse4-6).  In these diverse 
conditions, the atrophying muscles show increased rates of protein degradation primarily 
through activation of ATP-dependent ubiquitin-proteasome pathway and a common series of 
transcriptional adaptations that together constitute an atrophy programs3, 6).  During atrophy, 
there is an increase in the amount of ubiquitin-protein conjugates and increased transcription of 
components of the ubiquitin pathway.  The protein induced most dramatically during atrophy is 
the muscle-specific ubiquitin-ligase, atrogin-1 (MAFbx)4, 7).  mRNA for atrogin-1 increases 8-40 
fold in at all types of atrophy studied, and this increase precedes the onset of muscle weight 
loss4, 8).  Moreover, knockout animals lacking atrogin-1 show a reduced rate of muscle atrophy 
after denervation4, 9). 
On the other hand, induction of muscle hypertrophy by increased load is accompanied by 
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the increased expression of insulin-like growth factor (IGF-1)1, 9, 10).  When IGF-1 levels were 
enhanced using a muscle-specific promoter in transgenic mice, increased muscle size resulted11, 
12).  Also, additional of IGF-1 in vitro to differentiated muscle cells promotes myotube 
hypertrophy, supporting the concept that hypertrophy can be mediated by pathways activated by 
autocrine or paracrine sources of IGF-111).  During adaptive hypertrophy in adult muscle and in 
IGF-1-induced myotube hypertrophy, serine/threonine kinase (Akt) is phosphorylated and 
activated.  Additionally, hypertrophy elicits the direct and indirect targets downstream of Akt 
include glycogen synthesis kinase3 (GSK3), the mammalian target of rapamycin (mTOR), 
p70S6K, and eukaryotic initiation factor 4E binding protein 1 (4EBP-1), key regulatory protein 
involved in translation and protein synthesis1, 4).  Moreover, IGF-1 treatment or over-expression 
of IGF-1 improved dystrophic phenotype in skeletal muscle by hypertrophic signal pathway via 
phosphorylation of Akt1, 4, 13, 14). 
Duchenne muscular dystrophy (DMD) is an X-linked progressive disorder caused by a 
defect in the DMD gene, which encodes dystrophin15).  Dystrophin is a 427 kDa cytoskeletal 
protein that is normally located on the subsarcolemma and fixed by interaction with dystrophin-
associated proteins (DAPs), some of which span the membrane16-19).  This protein complex links 
the cytoskeleton of myofibers to the extracellular matrix to maintain the integrity of the 
sarcolemma.  The lack of dystrophin in DMD causes a secondary loss of DAPs in the 
sarcolemma and leads to massive muscle necrosis, resulting in cardiomyopathy and early death.  
Unfortunately, there is no treatment available to stop the progression of this devastating 
neuromuscular disorder other than corticosteroids.  Of the various therapeutic strategies for 
DMD being developed, up-regulation of utrophin has received considerable attention over the 
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last few years. 
Utrophin is a 395 kDa cytoskeletal protein with a high degree identity with dystrophin at 
the amino acid level and is an autosomal homologue of dystrophin20, 21).  It is ubiquitously 
expressed in most tissues.  In embryonic and neonatal skeletal muscles, it is expressed both 
synaptically and extra-synaptically.  In adult skeletal muscle, it is found mostly at the 
postsynaptic membrane of the neuromuscular junction (NMJ) and the myotendinous junction22, 
23).  
X chromosome-linked muscular dystrophy (Mdx) mice completely lack the expression of 
dystrophin, but the signs and symptoms of DMD are not progressive until later in the course of 
the disease.  This mild phenotype can be at least partly explained by up-regulation of utrophin at 
the sarcolemma24, 25).  Additional studies have shown that utrophin is present in greater amounts 
in small caliber muscle fibers of mdx mice26, 27) and small or regenerating muscle fibers of DMD 
patients28, 29).  In contrast, utrophin null-mdx (dko) mice have a severe myopathic phenotype that 
is lethal within 20 weeks of birth30).  
Previous transgenic (Tg) experiments showed that overexpression of utrophin at the 
sarcolemma compensates for the lack of dystrophin and ameliorates dystrophic phenotypes in 
dystrophin-deficient mdx mice, where components of DAPs had been restored31-33).  Similarly, 
adenovirally transduced utrophin ameliorates dystrophic changes in mdx mice34).  Yamamoto et 
al.35) showed that the immune response to adenovirally transferred E-galactosidase (E-gal) 
expression evoked up-regulation of endogenous utrophin, resulting in partial improvement of 
mdx phenotypes35).  
In addition, utrophin expression is up-regulated with Ca2+ inflow into cytoplasm through 
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the damaged muscle cell membrane36).  Further, among several DAPs, only neuronal NOS 
(nNOS) quickly dislocated from sarcolemma to the cytoplasm and its nNOS induced NO 
production in the cytoplasm during tail suspension, a model of unloading-induced muscle 
atrophy37) and it is also well known that L-arginine, the NO substrate induced up-regulation of 
endogenous utrophin expression38).  
These data suggested the not only systemic up-regulation of utrophin in DMD patients 
may lead to an effective treatment for this devastating disorder but also possibility that the 
muscle atrophy was repressed by up-regulation of utrophin expression.  However, the regulatory 
mechanism of utrophin expression is not fully understood yet. 
Transcriptional regulation of the utrophin gene is more complicated than previously 
pictured.  Two full-length utrophin mRNAs, A and B, which encode different N-termini, are 
driven by two distinct promoters39, 40).  Both A- and B-utrophin mRNAs are expressed in a 
tissue-specific manner, and an immunohistochemical study showed that A-utrophin is expressed 
in the NMJ, choroid plexus, pia mater, and renal glomerulus and tubule.  On the other hand, B-
utrophin is expressed in vascular endothelial cells25).  Several short C-terminal utrophin 
isoforms have been also reported, as found in dystrophin41).  To elucidate the transcriptional 
regulation of the utrophin gene, a more powerful tool is engineering an in vivo mouse model 
carrying a reporter gene.   
Recently, Takahashi et al.42) generated a transgenic mouse (Gnls) in which the LacZ gene 
was driven by the 5385-bp 5’-flanking region containing the A-utrophin promoter42).  
Expression of E-gal protein and mRNA derived from the transgene coincided well with the 
endogenous expression of utrophin in liver, testis, colon, submandibular gland, and small 
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intestine, but E-gal expression was extremely low in skeletal and cardiac muscle.  These results 
suggested that muscle repressor elements may be present in the 5385-bp region or that another 
regulatory element outside the region might be required for the expression in striated muscle.  
Comparable results were found by Weir et al.43) by using a transgene covering 3.8 kb of the 
mouse promoter region, which included the 1.3-kb reporter sequence characterized by Dennis et 
al 39).  
The downstream utrophin enhancer (DUE) region was identified by Galvagni and 
Oliviero44)? and located about 9 kb downstream of the second intron.  The upstream utrophin 
promoter is under the control of DUE24, 44).  In the present study, therefore, we generated 
transgenic mice (DUE Tg) in which DUE was added upstream of the 5385-bp 5’-flanking 
region and analyzed the expression pattern of the transgene in several tissues.  The present study 
found that the LacZ genes were expressed in skeletal and cardiac muscles.  These data are very 
relevant to finding a way to up-regulate utrophin expression, and DUE mice as well as the 
primary cells derived from the mice are available for that purpose.  
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3. Material and Methods 
 
3.1. Construction of transgene and generation of transgenic mice 
To further investigate the utrophin A promoter activity in report of Takahashi et al.42), 
genomic fragments containing the 5’ end of the mouse A-utrophin gene were cloned from a 
129Sv mouse genomic library (Stratagene, Texas, USA).  One clone contained the 5385 bp 5’-
flanking region of the A-utrophin gene, the complete exon 1A, and the first 59 bp of the exon 2 
untranslated region.  The genomic fragment was fused in-frame to an nls (from SV40T antigen)-
tagged LacZ gene45) (pCMVb, Clontech, California, USA), followed by a rabbit E-globin polyA 
signal in Bluescript II (Stratagene, Texas, USA)42).  Furthermore, we inserted the 129-bp 
utrophin enhancer region that is found in utrophin gene intron 244) upstream of this fragment 
(Fig. 1). 
 
 
 
 
 
 
 
 
 
 
exon 1A exon 2
Downstream utrophin enhancer 
(129 bp: DUE)
5385 bp 7075 bp 3203 bp
5’-end of the utrophin gene LacZ
nls rabbit E-globin polyA
Southern probe
DUE
Fig. 1 Diagram of the transgene used in this study. 
The genomic fragment (12.9 kb), which contained the 129-bp DUE, 5385-bp 5’-flanking region of the 
A-utrophin gene, exon 1A, intron 1, and the first 59 bp of exon 2 UTR, was fused in-frame to the nls-
tagged LacZ gene. The black bar indicates the Southern probe used to determine genotypes.
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The DNA fragment containing the transgene expression cassette was purified from 
agarose gel and injected into fertilized C57BL/6J eggs by YS Institute (Utsunomiya, Tochigi, 
Japan) (Table 1).  
 
 
 
 
 
 
We obtained two transgenic F0 (downstream utrophin enhancer/A promoter-nls LacZ 
transgenic mice), and two transgenic lines were established by mating the founders with 
C57BL/6J mice (B6) (Fig. 2). 
 
 
 
 
 
 
 
 To obtain transgenic mdx (Tg/mdx) male mice, we mated Tg male mice with mdx female 
mice (Fig. 3). 
 
Table 1  Summary of generation of Tg mice.
Fig. 2  Determination of copy numbers in Tg mice by Southern blotting. 
The vector plasmids containing the transgene served as a standard to estimate the number 
of copies of the transgene.
implanted eggs
F0
Tg positive F0
Number
523
129
2 ( ? 1, ? 1 ) line 1, line 2
line 1 line 2
1 2 5 10 20 50
Copy number
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3.2. Animals 
B6 and mdx mice aged 5-12 weeks, Tg mice and their wild littermates aged 3-18 weeks, 
and Tg/mdx mice aged 3-7 weeks were used.  All animals were housed in a separate room at a 
temperature of 20-22? and under an artificial lighting regime (12 hour light/12 hour dark).  
Animals were sacrificed by cervical dislocation.  All protocols were approved by the 
Institutional Animal Care and Use Committee of the National Institute of Neuroscience and 
were performed in compliance with the “Guide for the Care and Use of Animals” of the 
Division of Laboratory Animal Resources. 
 
3.3. Genotyping 
Tg mice were screened by Southern blotting of genomic DNA from their tails. Genomic 
DNA was isolated using a lysis buffer (50 mM Tris-HCl, pH 8.0, 0.1 M NaCl, 20 mM EDTA, 
1% SDS) with proteinase K (0.15 mg/ml) and pronase E (1 mg/ml) digestion.  Genomic DNA 
(10 Pg) was digested by BamH? , separated on a 0.8% agarose gel, and transferred to 
Hybond-N+ membranes (Amersham Biosciences, Buckinghamshire, UK).  A 3072-bp DNA 
Fig. 3  Generation of Tg/mdx mice. 
The bold box indicates the Tg/mdx male mice used in this study.
Tg mouse
? (XY)
mdx
? (X’X’)
Tg/mdx
? (X’Y)
mdx
? (X’Y)
Tg/mdx carrier
? (XX’)
mdx carrier
? (XX’)
F0
F1
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fragment of the LacZ gene was labeled with 32P-dCTP as a Southern probe, and hybridized 
with membranes at 65? overnight.  The membranes were then washed extensively (2?SSPE, 
0.1% SDS; 1?SSPE, 0.1% SDS; 0.1?SSPE, 0.1% SDS) at 65? and analyzed by BAS 2500 
(Fuji Film, Tokyo, Japan). 
 
3.4. Isolation of total RNA from mice and myogenic cells 
3- to 8-week-old Tg mice and their wild-type littermates were sacrificed, and tissues were 
isolated and rapidly frozen in liquid nitrogen.  Total RNA was isolated from frozen tissues and 
myogenic cells using TRIzol reagent (Invitrogen, California, USA) according to the 
manufacturer’s protocol.  
 
3.5. Reverse transcription (RT)-PCR and quantitative real-time PCR (q-RT-PCR) 
RT was performed with 1.0 Pg of total RNA using a QuantiTect® Reverse Transcription 
Kit (Qiagen, Hamburg, Germany) according to the manufacturer’s protocol.  PCR was 
performed using LacZ sense (5’-CGACATTGGCGTAAGTGAAG-3’) and antisense (5’-
ATCGCCATTTGACCACTACC-3’) primers for 30 cycles (denaturation at 95? for 1 minute, 
annealing at 60? for 30 seconds, and extension at 72? for 1 minute).  As a control for the 
generation of PCR products due to residual contamination of genomic DNA, an equivalent 
amount of RNA that had not been treated with RT was also processed in parallel.  The RT-PCR 
products of all samples were compared with the levels of a housekeeping gene, 18s rRNA, 
amplified with the following primer pair: sense (5’-TACCCTGGCGGTGGGATTAAC-3’) and 
anti-sense (5’-CGAGAGAAGACCACGCCAAC-3’) primers.  The levels of various cDNAs 
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were determined by q-RT-PCR using SYBR Green from ABI PRISM 7700 (Applied Biosystems, 
California, USA).  Each result shows the average of 3 or 4 samples.  The LacZ and 18s rRNA 
primer sequences are described above.  A-utrophin: sense (5’-ATGGCCAAGTATGGGGACC 
TTG-3’) and anti-sense (5’-GTGGTGAAGTTGAGGACGTTGAC-3’) primers; myogenin: 
sense (5’-CATGGTGCCCAGTGAATGCAACTC-3’) and anti-sense (5’-TATCCTCCACC 
GTGATGCTGTCCA-3’) primers; and MEF2C: sense (5’-TGGACAACAAAGCCCTCAGCAG 
GT-3’) and anti-sense (5’-AATCCCTGCTTCGTTCCCTCTGC-3’) primers were designed for 
q-RT-PCR.  18s rRNA mRNA was amplified as an internal control. 
 
3.6. Histochemical analyses 
After Tg and wild-type mice were sacrificed, the cerebrum, cerebellum, submandibular 
gland, lung, liver, kidney, small intestine, colon, testis, tibialis anterior (TA) and gastrocnemius 
(GC) muscles, diaphragm, and heart were isolated and frozen in liquid nitrogen-cooled 
isopentane.  Cryosections (7 Pm) from several tissues were stained with hematoxylin and eosin 
(H&E) and with 5-bromo-4-chloro-3-indolyl-E-D-galactopyranoside (X-gal; Wako Chemicals, 
Tokyo, Japan) according to the method of Ishii et al.46). 
 
3.7. Immunohistochemical analyses 
Serial transverse cryosections (7 Pm) from different tissues were placed on slides, then 
dried and fixed in acetone for 10 minutes at –20?.  We carried out immunohistochemical 
analysis with a rabbit polyclonal antibody against human utrophin (UT-2) that recognizes amino 
acid positions 1768-207847).  The primary antibodies were detected with Alexa 488-labeled goat 
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anti-rabbit IgG (Molecular Probes, California, USA).  The nucleus was stained with TOTO-3 
iodide (Molecular Probes, California, USA).  The NMJ was stained with Alexa 594-labeled D-
bungarotoxin (D-BTX) (Molecular Probes, California, USA).  Signals were recorded photo-
graphically with a laser-scanning confocal imaging system (TCSSP™, Leica, St. Gallen, 
Switzerland). 
 
3.8. Cardiotoxin injection  
To cause muscle degeneration, we injected 100 Pl of cardiotoxin (CTX) of Naja naja atra 
venom (10 PM in saline, Wako Chemicals, Tokyo, Japan) into the right TA and GC muscles of 
5- to 7-week-old Tg mice using a 29-gauge needle.  The concentration of CTX was determined 
according to the method of Couteaux et al.48).  CTX-injected Tg mice were sacrificed 1-14 days 
after injection.  The CTX-injected and contralateral non-injected TA and GC muscles were 
isolated and frozen in liquid nitrogen-cooled isopentane.  Cryosections (7 Pm) were stained with 
H&E and X-gal.  At the same time, serial cryosections (7 Pm) were stained with UT-2 together 
with Alexa 594-labeled D-BTX.  Total RNA was isolated from these frozen tissues. 
 
3.9. Cell preparation and culture 
Mouse-derived mononucleated cells were prepared from DUE and Gnls Tg mice and 
C57BL/6J mice according to the method of Rando and Blau49).  Primary myoblasts were 
cultured alone with growth medium (GM): F-10 containing 20% FBS, 1% penicillin-
streptomycin (Invitrogen, California, USA), and 2.5 ng/ml bFGF (Invitrogen, California, USA) 
in collagen-coated dishes (Iwaki, Tokyo, Japan) or chamber slides (Nalge Nunc, New York, 
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USA) coated with collagen type ? (Upstate, Massachusetts, USA).  For differentiation, the 
medium was changed to a differentiation medium (DM; 5% horse serum in DMEM) and 
cultured 5 days. GM and DM were replenished every 24 hours50).  
 
3.10. Statistics 
Statistical differences were determined by Student’s unpaired t-test.  All data are 
expressed as means?SEM.  Statistical significance was defined as p < 0.05. 
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4. Results 
 
4.1. Generation of downstream utrophin enhancer/A promoter-nls LacZ transgenic (DUE 
Tg) mice  
Two F0 ‘founder’ mice were identified by Southern blotting analysis using a LacZ cDNA 
probe, and two transgenic lines were established (Table 1).  The approximate numbers of 
transgene copies were about 15 in line 1 or about 2 in line 2 (Fig. 2).  The levels of transgene 
expression in several tissues were determined by RT-PCR (Fig. 4) and q-RT-PCR (Fig. 5).  
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Fig. 4  Expression levels of transgene mRNA from several tissues in Tg mice.
18s rRNA are used as a control gene. Negative control consisted of RT mixtures 
in which reverse transcription enzyme was replaced with RNase-free water.
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High levels of transgene mRNA expression were detected in the submandibular gland, 
testis, lung, colon, and small intestine of DUE line 1 Tg mice and in the submandibular gland 
and testis of DUE line 2 Tg mice.  The signals were weakly detected in other tissues of DUE 
line 2 Tg mice, probably because there were fewer copies of the transgene. 
 
 
Submandibular gland
mRNA expression (arbitrary units)
Cerebrum
Cerebellum
Lung
Heart
Diaphragm
Liver
Kidney
Testis
Colon
Small intestine
TA muscle
GC muscle
DUE line 1
0 1 2 3 4 2005 250
DUE line 2
0 1 2 3 4 15
Fig. 5  Quantification of mRNA expression levels from several tissues in Tg mice. 
18s rRNA are used as control gene. The ratio of the transgene to 18s rRNA is shown 
as the means?SEM of four independent experiments performed in triplicate.
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4.2. Comparison of E-gal and endogenous utrophin expression in DUE Tg mice 
To compare E-gal expression derived from the transgene with endogenous utrophin 
expression, cryosections were stained with X-Gal, and then serial cryosections were stained 
with either H&E or UT-2, a polyclonal antibody against human utrophin47) (Figs. 6-8).  UT-2 
recognized only the full-length A- and B-utrophin47).  The present study showed that E-gal 
expression coincided well with endogenous utrophin expression in the liver, testis, colon, 
submandibular gland (Fig. 6), small intestine, kidney and lung (Fig.7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Utrophin
TOTO-3
Liver Colon Testis 
Submandibular
gland 
H&E
X-Gal H
H
V
L
C
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SD
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ST
ST
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SD
Fig. 6  Expression of endogenous utrophin and E-gal in DUE Tg mice.
Serial cryosections of tissues (liver, testis, colon and submandibular gland) from 7-week-old DUE line 1 
Tg mice were stained with H&E (top), X-Gal (middle), and a polyclonal antibody against utophin (UT-2; 
green) (bottom). Nuclei were stained with TOTO-3 (blue). V, terminal hepatic venule ; Si, sinusoid ; H, 
hepatocyte ; ST, seminiferous tubule ; L, Leydig cell ; S, Sertoli cell ; C, capillary ; CM, inner circular 
muscle layer ; G, goblet cell ; LM, outer longitudinal muscle layer ; MM, muscularis mucosa ; SD, 
striated duct ; Sc, serous secretory cell ; SA, serous acinus ; Bar, 100 Pm.
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When compared with E-gal expression in Gnls Tg mice, expression levels of the transgene 
in DUE Tg mice were similar in the liver, testis, colon, submandibular gland, and small intestine, 
but were elevated in the kidney and lung.  In addition, when transgene expression was examined 
at the protein level, the levels were higher in DUE line 1 Tg mice than those in line 2 Tg mice. 
In the liver, the nuclei of hepatocytes, but not sinusoid lining cells, were strongly stained 
with X-gal, while endogenous utrophin was detected in the margins of hepatocytes along 
sinusoids and terminal hepatic venules.   
In the testis, E-gal activity was found in Sertoli cells in the basal compartment of the 
seminiferous tubules, but not in the adluminal compartment, and in Leydig cells in the 
Utrophin
TOTO-3
Small 
intestine Kidney Lung 
H&E
X-Gal
RC GI
MM
C
G
P
Vi
Vi
CM
LM
Cr
AC
RC
AC
C
GI
AC
Fig. 7  Expression of endogenous utrophin and E-gal in DUE Tg mice.
Serial cryosections of tissues (small intestine, kidney, and lung) from 7-week-old DUE line 1 Tg mice 
were stained with H&E (top), X-Gal (middle), and a polyclonal antibody against utophin (UT-2; green) 
(bottom). Nuclei were stained with TOTO-3 (blue). Cr, crypt ; P, Paneth cell ; C, capillary ; RC, renal 
cortex ; Gl, glomerulus ; AC, alveolar cells ; Bar, 100 Pm.
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interstitial supporting tissues between the seminiferous tubules.  Consistent with this 
observation, endogenous utrophin signals were found along the basement membrane of the 
seminiferous tubules and Leydig cells.  
In the colon, E-gal-positive nuclei were found in goblet cells in large intestinal glands.  
Endogenous utrophin signals were found along the basement membrane of large intestinal 
glands and the muscularis mucosa.  
In the submandibular gland, the nuclei of both serous and mucous secretory cells were 
clearly stained with X-gal.  The striated duct epithelia lacked the E-gal signal.  Endogenous 
utrophin was detected along the basement membrane of serous and mucous acini, but not of 
striated ducts.  
In the small intestine, E-gal-positive nuclei were found in goblet cells and Paneth cells 
which lie in epithelia of the bases of villi and crypts.  Endogenous utrophin signals were found 
along the basement membrane of villi and crypts and in the muscularis mucosa.    
In the kidney, E-gal-positive nuclei were found in the epithelia of cortical renal tubules, 
but not in glomeruli.  It is not clear whether E-gal positive nuclei were present in proximal 
convoluted tubules, distal convoluted tubules, collecting tubules, or collecting ducts although 
endogenous utrophin was found along the basement membrane of cortical renal tubules, 
collecting ducts of the renal medulla and Bowman’s capsules, and in glomerular capillaries.  
In the lung, E-gal-positive nuclei were found in alveoli, but not in terminal bronchiole 
epithelia.  It is not clear whether E-gal-positive nuclei were present in type ? or type ? 
pneumocytes.  Endogenous utrophin was found in alveolar cells and terminal bronchiole 
epithelia.  In these tissues, endogenous utrophin seemed to localize at the plasma membranes of 
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cells adjacent to the basement membranes. 
 
 E-gal expression in cerebrum, cerebellum, heart, and skeletal muscle of DUE Tg mice 
In a previous study of Gnls Tg mice, we did not detect any E-gal expression in the 
cerebrum, cerebellum, heart, and skeletal muscle42), but we found E-gal expression in these 
tissues in the DUE line 1 Tg mice (Fig. 8). 
In the cerebrum, E-gal positive nuclei were found in ependymal cells of the choroid 
plexus and in fibroblastic cells of the pia mater along the basal membrane.  Consistent with this 
observation, endogenous utrophin was detected in the choroid plexus and pia mater.  
In the cerebellum, E-gal-positive nuclei were found in stellate and basket cells of the 
molecular layer, but not in fibroblastic cells of the pia mater, although endogenous utrophin is 
expressed in the pia mater of the cerebellum.  Our results indicate that the distal utrophin 
enhancer cannot activate expression of the transgene in fibroblastic cells of the pia mater in the 
cerebellum, although it can enhance the expression in fibroblastic cells of the pia mater in the 
cerebrum.  
In the heart, E-gal is expressed in myocardial nuclei located in the vicinity of intercalated 
disks. Endogenous utrophin expression was found in intercalated disks and T tubules of cardiac 
muscle.  
In skeletal muscle, A-utrophin is expressed in NMJs, peripheral nerves, and larger blood 
vessels.  We detected E-gal expression not only in myonuclei located close to NMJs but also in 
myonuclei remote from NMJs in DUE Tg skeletal muscles, but it is not clear whether or not E-
gal-positive nuclei were present in nerves and blood vessels.  Expression of the transgene was  
 -21-
not detected in the cerebrum, cerebellum, heart, and skeletal muscle in DUE line 2 Tg mice. 
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 E-gal expression was augmented in CTX-injected and dystrophin-deficient DUE Tg 
mice 
The present study examined expression of the transgene under a condition in which 
expression of endogenous utrophin is augmented.  Recently, Galvagni et al. reported that the 
transcription of A-utrophin was activated in regenerating muscle under DUE control 24).  
 Therefore, the present study injected CTX into TA muscles of Tg mice to damage muscle 
fibers, and analyzed E-gal expression during muscle regeneration (Fig. 9).  The E-gal signals 
were strongly detected in extrasynaptic regions at 5 or 7 days after CTX injection (Fig. 9A).  
Moreover, transgene mRNA levels were also elevated at 3 or 5 days after CTX injection (Fig. 
9B).  These transgene expressions coincided well with the expression of endogenous utrophin.  
It is interesting to note that transgene expression was also augmented in CTX-injected DUE line 
2 Tg mice, although transgene expression was not detected in non-injected skeletal muscle of 
these mice (Fig. 10). 
Utrophin was also up-regulated in the dystrophic process of mdx mouse skeletal muscle.  
To examine the transgene expression in dystrophin-deficient muscle, we mated DUE line 2 Tg 
male mice with mdx female mice (Fig. 3).  Endogenous utrophin was overexpressed along the 
sarcolemma, and some myonuclei of TA and GC muscles of DUE line 2 Tg/mdx male mice 
were positive for E-gal (Fig. 11A).  We also found slightly elevated mRNA levels derived from 
the transgene in TA and GC muscles of DUE line 2 Tg/mdx mice by RT-PCR (Fig. 11B). 
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Fig. 10  Transgene expression during muscle regeneration in CTX-injected DUE line 2 Tg mice.
Cryosections of muscles were stained with H&E (top), X-Gal (middle), and a polyclonal antibody 
against utophin (UT-2; green) (bottom). Nuclei were stained with TOTO-3 (blue). The NMJs were 
identified with D-BTX (red). TA muscle of DUE line 2 Tg mice at 0, 5, or 7 days after CTX injection; 
bar, 100 Pm
H&E
X-Gal
Utrophin
TOTO-3
D-BTX
CTX5 days CTX7 daysNot injected
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Fig. 11 Transgene expression in skeletal muscle of DUE Tg mice cross-bred with dystrophin
deficient mdx mice.
(A)
(B)
line 2 Tg/mdx
TA
line 2 Tg/mdx
GC
H&E
X-Gal
Utrophin
TOTO-3
D-BTX
line2 TA
Tr
an
sg
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18
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(A) Cryosections of muscles were stained with H&E (top), X-Gal (middle), and a polyclonal antibody 
against utophin (UT-2; green) (bottom). Nuclei were stained with TOTO-3 (blue). The NMJs were 
identified with D-BTX (red). TA and GC muscles of DUE line 2 Tg/mdx mice. Arrow, E-gal-expressing 
nuclei; bar, 100 Pm. (B) Representative photomicrographs of EtBr-stained agarose gels depicting cDNA
products for the transgene and 18s rRNAs from RT-PCR analysis of total RNA from TA and GC 
muscles of DUE line 2 Tg/mdx mice. As a control, the TA muscle of DUE line 2 Tg mice was used. 
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4.5. Transgene expression was activated in late stage muscle differentiation in vitro  
We cultured primary myoblasts from skeletal muscles of DUE Tg and Gnls Tg mice, and 
some of the cultures were induced to differentiate.  Those cells were stained with X-Gal (Fig. 
12).  Expression of the transgene was detected in primary myoblasts of DUE Tg mice but not in 
those of Gnls Tg mice (Figs. 12, 13).  In addition, the expression was up-regulated in myotubes 
in the DUE Tg mice, but not altered in myotubes of the Gnls Tg mice (Fig. 13).  The up-
regulation of the transgene was further investigated at the mRNA level, and it was found at a 
later stage of muscle differentiation.  Very interestingly, the expression profiles of E-gal and 
endogenous utrophin were in accordance with that of MEF2C, but not compatible with that of 
myogenin. 
 
 
 
 
 
 
 
 
 
 
 
 
Myoblast Myotube
DUE Tg
Gnls Tg
X-Gal Phase-contrast X-Gal Phase-contrast
Fig. 12  Transgene expression in primary cultured myoblasts and myotubes from DUE Tg mice.
Primary cultured myoblasts and myotubes from DUE Tg mice and Gnls Tg mice were stained with X-
Gal. Image of myotube after 3 days in differentiation medium. Bar, 200 Pm.  
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(B)
(A) and (B) Quantification of q-RT-PCR products for transgene, A-utrophin, myogenin, and MEF2C 
optimized to expression of 18s rRNA in primary myoblasts and myotubes from DUE Tg mice and Gnls
Tg mice. The ratios of the transgene, A-utrophin, myogenin, and MEF2C to 18s rRNA are shown as the 
means?SEM of four independent experiments performed in triplicate. *P < 0.05, ** p < 0.01 and ***P
< 0.001 (vs. 0 time).
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Fig. 13  Quantification of mRNA expression in primary cultured myoblasts and myotubes from   
DUE Tg mice and Gnls Tg mice.
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5. Discussion 
 
Recently, Takahashi et al.42) reported  that a 5385-bp 5’-flanking region of the utrophin 
gene containing the A-utrophin core promoter drives high levels of transgene expression in liver, 
testis, colon, submandibular gland, and small intestine, but not in heart and skeletal muscle.  The 
present study demonstrated that addition of DUE to the 5385-bp 5’-flanking region enabled 
transgene expression in a pattern that was almost identical to that endogenous utrophin 
expression (Tables 2, 3).  Moreover, E-gal-expressing nuclei were basically located in the 
vicinity of the endogenous utrophin expression in heart and skeletal muscle.  
In regenerating muscle of DUE Tg mice and skeletal muscle of DUE Tg/mdx mice, which 
lack dystrophin, the transgene expression was considerably up-regulated.  Another research 
group also reported that utrophin transcription was controlled by DUE activity in regenerating 
muscle and that its activity was dependent on an AP-1 binding site24).  They injected marcain 
into TA muscles of CD1 mice and found elevation of members of the AP-1 factor, c-fos, fosB, 
fra-1, fra-2, c-jun, junB and junD, but we also found distinct elevation of c-fos and fra-1 mRNA 
in our regeneration system (unpublished observations). 
We cultured primary myogenic cells from DUE Tg mice and found that transgene 
expression was up-regulated during the differentiation process.  Moreover, these transgene 
expression patterns corresponded to the endogenous utrophin expression profile.  This result 
indicates that the participation of DUE in utrophin expression during muscle regeneration might 
depend largely on DUE activity in the later stage of muscle differentiation.  It is intriguing to 
note that transgene and endogenous utrophin expression patterns coincided with the expression  
 -29-
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profile of MEF2C, but not that of myogenin.  It has been already reported that MEF2C mediates 
the promoter activity of c-jun51).  The MEF2C-c-jun pathway is one of the candidates to regulate 
utrophin expression via DUE.  Analysis of the transcriptional factors that interact with DUE 
sequences, particularly the AP-1 site, would be very intriguing and should be clarified by a 
future study.  
The present study also demonstrated that the addition of DUE augmented transgene 
expression not only in the heart and skeletal muscle but also in other tissues such as the cerebral 
pia mater and choroid plexus and the cerebellar choroid plexus and molecular layer.  In addition, 
transgene expression was elevated in the kidney and lung of DUE Tg mice compared with that 
of Gnls Tg mice, although it is necessary to consider the difference in transgene copy numbers.  
Table 3. Summary of E-gal expression in Gnls Tg mice and DUE Tg mice.
Visceral organs
Gnls DUE line 1 DUE line 2
Liver ?? ?? ?
Testis ??? ??? ?
Colon ?? ?? ?
Submandibular gland ??? ??? ?
Small intestine ? ? ?
kidney ? ? ?
Lung ? ?? ?
Cerebrum ? ?? ?
Cerebellum ? ?? ?
Heart ? ?? ?
TA muscle ? ? ?
E-gal expression
Tg mice were sacrificed at 4-7 weeks old, and E-gal expression was examined in several tissues. 
No E-gal positive nuclei were found in non-transgenic littermates. E-gal expression levels are 
shown as:?, none; ?, trace; +, weak; ++, moderate;  and +++, strong.
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These results suggest that DUE activity is not muscle specific, and this suggestion is consistent 
with the data of Galvagni et al.44).  In their report, a construct of DUE added to the utrophin 
promoter was transiently transfected to various cells and revealed that DUE enhanced utrophin 
promoter activity not only in C2C12 myoblasts but also in HeLa cells and RD cells. 
However, the addition of DUE cannot fully explain the transcriptional regulation of 
utrophin.  In the cerebrum and cerebellum, endogenous utrophin was expressed in the pia mater 
and choroid plexus.  We found E-gal-positive nuclei in the cerebral pia mater along the basal 
lamina, but did not find many E-gal-positive nuclei in the cerebellum.  There are several 
possibilities to explain this discrepancy.  The first possibility is that the domain that regulates 
utrophin expression in the pia mater of the cerebellum is different from that for the pia mater in 
the cerebrum.  The second possibility is that transcription of utrophin might be less active in 
fibroblastic cells of the pia mater of cerebellum than those of the cerebrum.  However, a 
fundamental difference between fibroblastic cells in the cerebrum and those in the cerebellum 
has not been reported; further experiments are required to explain this discrepancy. 
The present study demonstrated that DUE is necessary for utrophin expression in skeletal 
muscle, but the increase in the utrophin expression level was much larger than the transgene 
expression in regenerated muscle.  Another research group also detected the increase in the 
abundance of A-utrophin protein in muscle from mdx mice but could not find any parallel 
elevation in the levels of utrophin transcripts25).  Therefore, A-utrophin expression may also be 
regulated at the post-transcriptional level.  Indeed, recent studies have shown that distinct cis-
acting elements within the utrophin 3’-untranslated region (UTR) were important not only for 
controlling the stability of utrophin transcripts in muscle cells but also for targeting them to 
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specific subcellular locations52, 53). 
Post-translational levels are also important for utrophin expression through stabilization 
of the protein. DAPs such as dystrophin, E-dystroglycan, D-dystroglycan, and D-sarcoglycan 
have been linked to regulation by protein degradation mechanisms including the ubiquitin-
proteasome pathway54) and calpain-mediated proteolysis55).  Inhibition of the proteasomal 
degradation pathway was found to rescue the expression levels of several DAPs in mdx mice54).  
Treatment of normal and DMD human myotubes with glucocorticoid induced utrophin protein 
without elevations in transcripts, and this was speculated to involve calpain inhibition56).  
It is likely that extrasynaptic expression of utrophin in skeletal muscle of DMD patients 
would ameliorate the dystrophic pathology, at least to some extent32, 33).  The results of this 
report demonstrate that DUE is indispensable to utrophin expression in skeletal muscle and 
heart.  To further investigate the up-regulation mechanisms of utrophin in both tissues, we need 
to search for transcription factors bound to DUE.  In addition, we established primary myogenic 
cell cultures from DUE Tg mice and found that utrophin up-regulation depends on the DUE 
motif during muscle differentiation.  These cells provide a high through-put screening system 
for drugs that can up-regulate utrophin expression in myogenic cells. 
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7. Concluding remarks 
 
Duchenne muscular dystrophy (DMD) is an X-linked progressive disorder caused by a 
defect in the DMD gene, which encodes dystrophin.  Utrophin is a 395-kDa cytoskeletal 
protein with a high degree identity with dystrophin at the amino acid levels and is an autosomal 
homologue of dystrophin.  Overexpression of utrophin is known to be ameliorated the 
dystrophinc phenotype muscle in mice.  However, the regulatory mechanism of the utrophin 
gene containing the A-utrophin core promoter has not been elucidated.  According to the recent 
study, the 5.4 kb 5’-flanking region of the utrophin gene containing the A-utrophin core 
promoter did not drives transgene expression in heart and skeletal muscle.  In order to clarify 
the regulatory mechanism of utrophin expression, therefore, we generated a nuclear localization 
signal-tagged LacZ transgenic (Tg) mouse, in which the LacZ gene was driven by the 129 bp 
downstream utrophin enhancer (DUE) and the 5.4 kb 5’-flanking region of the utrophin 
promoter. The levels of transgene mRNA expression in several tissues were examined by 
reverse transcription-polymerase chain reaction (RT-PCR) and quantitative RT-PCR (q-RT-PCR), 
and cryosections of several tissues were stained with hematoxylin and eosin (H&E) and 
5-bromo-4-chloro-3-indolyl-E-D-galactopyranoside (X-gal).  The results obtained in the 
present study are summarized as follows. 
1. In vivo study  
1) The transgene expression patterns were consistent with endogenous utrophin in several 
tissues including heart and skeletal muscle.  
2) Transgene expression was also up-regulated more in regenerating muscle than in 
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non-regenerating muscle.  
3) Utrophin expression was augmented in the skeletal muscle of DUE Tg/X chromosome-linked 
muscular dystrophy (mdx) mice through cross-breeding experiments.  
2. In vitro study  
1) We established cultures of primary myogenic cells from DUE Tg mouse and found that 
utrophin up-regulation during muscle differentiation depends on the DUE motif.  
2) MEF2C is one of the candidate factor to regulate utrophin expression via DUE because of 
Endogenous utrophin expression patterns coincided with expression profile of MEF2C.  
These results show that DUE is indispensable for utrophin expression in skeletal muscle 
and heart, and primary myogenic cells from this Tg mice provide a high through-put screening 
system for drugs that up-regulate utrophin expression. 
 -43-
8. Publication list 
 
??Shirato K, Motohashi N, Tanihata J, Tachiyashiki K, Tomoda A and Imaizumi K (2006) 
Effects of two types of inactivity on the number of white blood cells in rats. European 
Journal of Applied Physiology, 98:590-600 
 
??Shirato K, Tanihata J, Motohashi N, Tachiyashiki K, Tomoda A and Imaizumi K (2007) 
Beta2-agonist clenbuterol induced changes in the distribution of white blood cells in rats. 
Journal of Pharmacological Sciences, 104 (2):146-52 
 
??Tanihata J, Suzuki N, Miyagoe-Suzuki Y, Imaizumi K and Takeda S (2008) Downstream 
utrophin enhancer is required for expression of utrophin in skeletal muscle. Journal of 
Gene Medicine, 10 (6): 702-713  
 
 -44-
9. Oral presentation list 
 
??Oyama K, Wada T, Tachiyashiki K, Shirato K, Tanihata J, Motohashi N, Higashino Y, 
Suzuki K and Imaizumi K: Comparisons among three life-stages in capsaicin-induced 
changes of plasma energy substrate levels in rats. Japanese Journal of Physiology, 54 
(Supplement): S232 (2004) 
 
??Motohashi N, Tanihata J, Tachiyashiki K and Imaizumi K: In vivo effect of 
hydrocortisone on plasma energy substrate levels in rats. Japanese Journal of 
Physiology, 54 (Supplement): S233 (2004) 
 
??Tanihata J, Motohashi N, Tachiyashiki K and Imaizumi K: In vivo effect of synthesized 
glucocorticoid, dexamethasone on plasma energy substrate levels in rats. Japanese 
Journal of Physiology, 54 (Supplement): S233 (2004) 
 
??Adachi S, Tachiyashiki K, Tanihata J, Motohashi N and Imaizumi K: Effect of agonist, 
clenbuterol on plasma substrate, insulin and cyclic AMP levels in rats. Japanese Journal 
of Physiology, 54 (Supplement): S234 (2004) 
 
??Shirato K, Tachiyashiki K, Motohashi N, Tanihata J, Wada T, Ichinose T and Imaizumi 
K: Effects of hypokinesia/hypodynamia and agonist on white blood cell levels in rats. 
Japanese Journal of Physiology, 55 (Supplement): S110 (2005)  
 
??Tanihata J, Tachiyashiki K, Motohashi N, Shirato K, Wada T, Ichinose T and Imaizumi 
K: Effects of skeletal muscle hypertrophy and atrophy on muscle DNA, RNA and 
protein levels. Japanese Journal of Physiology, 55 (Supplement): S225 (2005) 
 -45-
??Motohashi N, Tachiyashiki K, Tanihata J, Ichinose T and Imaizumi K: Muscle 
atrophy-induced changes of cathepsin and dipeptide levels in rats. Japanese Journal of 
Physiology, 55 (Supplement): S225 (2005) 
 
??Shirato K, Tanihata J, Motohashi N, Tachiyashiki K, Tomoda A and Imaizumi K: Effect 
of E2-agonist, clenbuterol on the number of white blood cell in rats. FASEB Journal, 21 
(6): A936 (2007) 
 
??Shirato K, Motohashi N, Tanihata J, Tachiyashiki K, Tomoda A and Imaizumi K: Two 
types of inactivity-induced changes of the number of white blood cells in rats. FASEB 
Journal, 21 (6): A1392 (2007) 
 
